The best FP&A platforms for life sciences financial planning in 2026 are those purpose-built to handle R&D budget modeling, clinical trial cost tracking, and burn rate forecasting with investor-ready runway projections. Abacum, Jirav, Pigment and Anaplan are commonly evaluated by biotech and pharma finance teams for the ability to model probability-weighted pipeline scenarios, track CRO accruals, and generate board-ready reports that reflect the unique financial realities of drug development. Choosing the right platform depends on your company's stage, planning complexity, and whether you need milestone-based forecasting tied to clinical phase transitions.
Life sciences companies operate in a financial environment unlike any other industry. The combination of long development timelines, regulatory uncertainty, and capital-intensive R&D programs creates planning challenges that generic financial software simply cannot address. FP&A platforms for life sciences must account for enrollment-based cost drivers, IND-to-NDA budget structures, and the constant need to communicate runway scenarios to investors and board members who demand precision and transparency.
This guide compares platforms across the capabilities that matter most to biotech and pharma finance leaders, from clinical trial budgeting to burn rate modeling, so you can identify the right fit for your organization's specific needs.
Abacum is the AI-native FP&A platform finance trusts, and the business planning platform the whole company runs on. It runs on one governed layer of data, logic and context: data is the what, logic is the how, context is the why.
What to Look for in FP&A Software for Life Sciences Companies
Life sciences FP&A software must support R&D-centric budgeting, milestone-driven forecasting, and runway modeling that reflects the probabilistic nature of drug development. Generic financial planning tools lack the structural flexibility to handle these requirements without extensive customization.
When evaluating platforms, prioritize capabilities that map directly to how biotech and pharma companies actually operate. Clinical trial costs represent the largest budget category for most life sciences organizations, and these costs behave differently than typical operating expenses. They fluctuate based on patient enrollment rates, site activation timelines, and CRO contract structures that include pass-through costs and fee-for-service components.
The ability to model scenarios based on clinical milestones is essential. Your platform should allow you to build forecasts that adjust automatically when a program advances from Phase 1 to Phase 2, or when enrollment targets shift. This milestone-based approach differs fundamentally from the calendar-driven budgeting that works for other industries.
Integration capabilities matter significantly for life sciences finance teams. Your FP&A platform should connect with your ERP, clinical trial management systems, and cap table software to create a unified view of financial performance. For a deeper exploration of life sciences financial forecasting software capabilities, consider how forecasting-specific features complement broader planning functionality.
Grant accounting represents another critical requirement for many biotech companies. Platforms must support the tracking and reporting requirements associated with NIH grants, BARDA contracts, and other government funding sources that come with specific compliance obligations.
Understanding how industry-specific FP&A software differs from horizontal solutions helps clarify why life sciences companies need specialized tools. The domains of life sciences finance (clinical development, regulatory affairs, manufacturing scale-up) each introduce planning variables that generic platforms treat as afterthoughts rather than core functionality.
Top FP&A Platforms for Biotech and Pharma Compared
FP&A platforms commonly evaluated by biotech and pharma finance teams include Abacum, Jirav, Pigment, Anaplan and Datarails; confirm specifics with each vendor.
Abacum is an AI-native business planning platform built on one governed layer of data, logic and context, for finance teams from fast-scaling teams to global enterprises. It offers scenario planning, headcount planning tied to the budget and P&L, bottom-up department planning with finance approvals, and 700+ integrations via native, automated connections. For life sciences workflows such as clinical trial budgeting, burn rate tracking and investor reporting, confirm specifics with Abacum.
Abacum's AI Modeler lets finance describe a model in plain language and get a working model in minutes, and every model explains itself line by line. The agent proposes, the calculation engine computes every number, and nothing saves until you approve it. Abra, our AI agent, takes a plain-language question, routes it to the right expert agent (Modeler, Analyst, Reporter or Data Manager) and works from governed data, with every change approved first. Both are included at no extra cost.
Jirav is commonly evaluated for driver-based forecasting. Confirm life sciences fit, pricing and implementation details with Jirav.
Pigment is a flexible modeling platform for teams willing to build and maintain their own planning models. Your team or an implementation partner designs it and keeps it running, so confirm who will own the model after go-live.
Anaplan is commonly evaluated by organizations with complex, interconnected planning requirements. Confirm implementation complexity and cost with Anaplan.
Datarails is commonly evaluated by finance teams that want to keep working in Excel. Confirm specifics with Datarails.
For readers seeking a broader view of available options, the life sciences financial planning tools directory provides an expanded list of platforms serving this market. Those focused specifically on budgeting use cases should also explore budgeting software options for biotech companies to understand how dedicated budgeting tools compare to full FP&A platforms.
How Platforms Handle R&D Budget Modeling and Clinical Trial Costs
Platforms handle R&D budget modeling through driver-based approaches that connect clinical assumptions to financial outcomes, allowing finance teams to model costs based on enrollment rates, site counts, and protocol complexity rather than simple line-item projections.
Clinical trial budgeting represents the most complex area of life sciences financial planning. A single Phase 3 trial can span multiple years, involve dozens of clinical sites across different countries, and include cost categories ranging from investigator fees to central lab services to patient travel reimbursements. Effective platforms structure these costs in ways that reflect how they actually accrue.
CRO cost tracking requires particular attention. Contract research organizations typically bill through a combination of fixed fees, unit-based charges, and pass-through costs. Your FP&A platform should model each component separately, allowing you to forecast how changes in enrollment pace or protocol amendments affect total program costs.
The life cycle of a clinical program introduces planning challenges at each phase transition. Moving from Phase 2 to Phase 3 typically increases costs substantially, and platforms must support the scenario modeling needed to understand how different development paths affect overall R&D spend and company runway.
Probability weighting adds another layer of complexity. Not every program in your pipeline will succeed, and sophisticated financial planning requires adjusting expected costs and timelines based on historical success rates for each clinical phase. Platforms that support probability-weighted forecasting help finance teams present more realistic projections to investors and board members.
For detailed guidance on structuring clinical trial budgets within your FP&A platform, the resource on clinical trial budgeting and R&D planning software provides specific implementation approaches.
Burn Rate Forecasting and Runway Planning for Investor Reporting
Burn rate forecasting and runway planning require platforms that can model multiple scenarios simultaneously and present results in formats that satisfy investor and board reporting requirements. The best platforms automate the connection between operational assumptions and cash runway calculations.
For biotech companies, burn rate is not a static metric. It fluctuates based on clinical trial activity, hiring plans, and the timing of major vendor payments. Effective FP&A platforms model burn rate dynamically, showing how changes in any input variable cascade through to runway projections.
Investor reporting demands specific outputs. Board members and investors expect to see runway under multiple scenarios: typically a base case, an upside case reflecting faster-than-expected progress, and a downside case accounting for delays or setbacks. Platforms should generate these scenarios without requiring finance teams to maintain separate models for each.
The connection between clinical milestones and financing events adds strategic importance to runway planning. Many biotech companies time their fundraising around data readouts or regulatory submissions, and FP&A platforms must support the what-if analysis needed to understand how different milestone timelines affect financing requirements.
Cash runway calculations for life sciences companies must account for the lumpy nature of R&D spending. Unlike SaaS companies with relatively predictable monthly burn, biotech companies experience significant month-to-month variation based on clinical trial enrollment, manufacturing campaigns, and regulatory submission timelines.
The native FP&A for biotech webinar demonstrates practical workflows for building investor-ready burn and runway reports, showing how finance teams can reduce the manual effort involved in board preparation while improving the accuracy and consistency of their projections.
How to Match a Platform to Your Life Sciences Planning Complexity
Match the platform to your planning structure. Teams with one or two clinical programs usually need quick setup and clear runway reporting. Teams with several programs at different phases need milestone-linked scenarios, probability-weighted forecasts and board reporting. Organizations with portfolios across therapeutic areas need interconnected models and cross-program analysis. For each shortlisted vendor, confirm which of these structures it supports, and ask for a clear implementation plan with named owners and milestones.
For a comprehensive view of how financial planning tools for life sciences address different organizational contexts, consider how your current planning processes and team capabilities align with each platform's implementation requirements.
Build Board-Ready Biotech Financial Plans with Abacum
Abacum gives biotech and pharma finance teams one governed layer of data, logic and context for planning, with scenario planning, headcount planning tied to the budget and P&L, and bottom-up department planning with finance approvals. For clinical trial budgeting, burn rate and investor reporting workflows specific to life sciences, confirm specifics with Abacum.
Explore how Abacum's life sciences solution addresses the specific planning challenges facing biotech and pharma finance teams, from clinical trial budgeting through investor-ready runway reporting.
Ready to see Abacum in Action? Request a personalized demo.












